Pilot Study of Atorvastatin for Orthopedic Surgery Patients
NCT02197065 is a phase 2 interventional trial sponsored by Hospital for Special Surgery, New York. As of 18 Nov 2026, it is completed. It studies Atorvastatin and Placebo in Hip Fracture, Inflammation and 1 more condition. The registry lists an enrollment of 20 participants at 2 sites in 1 country. The registry lists a start date of 30 Sept 2014 and a primary completion date of 31 Jul 2016. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02197065 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Hospital for Special Surgery, New York |
| Enrollment | 20 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Hip Fracture, Inflammation and Myocardial Ischemia |
| Drugs | Atorvastatin and Placebo |
| Start | 30 Sept 2014 |
| Primary completion | 31 Jul 2016 |
| Study completion | 31 Jan 2017 |
| Last update posted | 2 Jul 2017 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital for Special Surgery
New York
- New York Presbyterian Hospital (cornell)
New York
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT02197065
Each answer restates registry values shown on this page.
What is NCT02197065?
NCT02197065 is a phase 2 interventional trial sponsored by Hospital for Special Surgery, New York. It studies Atorvastatin and Placebo in Hip Fracture, Inflammation and 1 more condition.
Who leads NCT02197065?
The registry names Anne R Bass, MD (principal investigator, Hospital for Special Surgery, New York) as the overall official.
Where does NCT02197065 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT02197065 study?
The registered drug and biological interventions are Atorvastatin and Placebo.
When did NCT02197065 end?
The registry lists a primary completion date of 31 Jul 2016 and a study completion date of 31 Jan 2017. The sponsor last updated the record on 2 Jul 2017.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.